http://www.moh.govt.nz/moh.nsf/Files/phr399/$file/phr399.pdf A cross-sectional survey of the prevalence of HIV and hepatitis
C virus (HCV) infection and related risk behaviours was carried out among
injecting drug users (IDUs) attending four needle and syringe exchange
programmes in New Zealand in December 1997.
Reuse of someone else's syringe, imprisonment within the previous year,
and being over 35 years of age were significant predictors for having
HCV antibody, after adjustment for duration and frequency of injecting
drug use, and type of drug used.
The arboviral disease, Barmah Forest virus disease, was notified for the
first time in New Zealand in January 1999.
Serological tests for the disease have only been available in New Zealand
since 1998.
hepb
http://uhs.berkeley.edu/Students/Immune/hepb.pdf California law requires first-time enrollees at the University
of California who are under 19 years of age to provide proof of immunization
or immunity against the Hepatitis B virus prior to enrollment.
#2 The individual named above has begun the Hepatitis B immunization series
and has received the following doses: Please copy this form and return
to the above address as each dose is received.
#4 The above named individual has a medical contraindication to Hepatitis
B immunization.
(If the applicant is 17 years of age or younger and is not an emancipated
minor, the parent, guardian or adult who has assumed responsibility for
the care and custody of the student must sign).
03_2003_GSN
For the past 17 years, the GSN has produced graduate nurses
in a collaborative research and service-driven environment where innovative
education and practice models improve health and quality of care.
The GSN is privileged to have a core group of faculty, students, alumni
and friends who value nursing and continue to build upon the school's
standing by developing great leaders.
Among our faculty Carol Bova, PhD, RN, ANP, coordinator of the Adult Ambulatory
NP program, holds a joint appointment as an assistant professor in the
GSN and the Department of Medicine.
Results of this study will also be valuable to clinicians, educators,
researchers and those who develop treatment guidelines for HCV/HIV co-infected
patients.
init_hepc_4303
The Governor included $1 million for hepatitis C in his budget
recommendations for next year and now the House is putting together their
budget.
Our message must be twofold - we must ask the House to fund hepatitis
C programs and also let them know that they have our support to raise
the revenues that may be necessary to do so.
Contact the three legislators listed below TODAY!
Message: Hepatitis C funding (line item 4513-1114) has been cut by over
73% in the past year, virtually eliminating programs for the 100,000 Massachusetts
residents infected with this potentially fatal disease.
The Coalition is coordinated by the Massachusetts Public Health Association,
an independent statewide non-profit organization working to improve the
health status of Massachusetts residents through education, advocacy and
coalition-building.
c_interv
http://www.hcet.org/pdf/resource/postconf/hepconf/c_interv.pdf Health Care Education and Training, Inc. (HCET), through a
cooperative agreement with the Centers for Disease Control and Prevention
(CDC), has initiated a project to provide training on viral hepatitis
to health care professionals.
In order to assess the training needs and the current status of counseling,
testing and treatment for viral hepatitis, a questionnaire was distributed
to the target clinics in February 2001.
The first part involved a small group process with clinic staff, and focused
on the categories outlined above.
The second part of the process involved interviews with a total of 37
individual clients from the chosen clinics.
HepatitisA.2.2000
CDInfo is a surveillance newsletter intended to promote prevention
of morbidity and mortality by providing useful data and practical recommendations
for clinicians, laboratorians and infection control personnel who diagnose,
treat and/or report infectious diseases in Chicago.
Between 1992 and 1999, 30 community areas experienced high or intermediate
rates of infection (see figure).
hepatitis A vaccine, free of charge, to all providers who participate
in the "Vaccine for Children" program.
PASSIVE PROPHYLAXIS & REPORTING: Immune globulin remains the mainstay
of prophylaxis for contacts to cases of hepatitis A. When administered
within two weeks following an exposure to hepatitis A virus, IG is greater
than 85% effective in preventing hepatitis A. Timely reporting is imperative
in order to intitiate any intervention.
nejm-anes-hepc-2000
hepatitis C virus (HCV) remain a major challenge.1 The main
source of HCV infection in developed countries was formerly transfusion
of contaminated blood and blood products but is now in-jection-drug use.2-4
In general, a potential risk factor can be established for about 90 percent
of all cases of HCV infection.3 One way of contracting HCV may be transmission
from infected medical personnel to susceptible patients during medical
care.
Our findings suggest that an anesthesiology assistant contracted HCV from
a chronically infected patient and subsequently transmitted the virus
to five other patients.
Supported in part by a grant to the German National Reference Center for
Hepatitis C.
hepatitis
AEROMEDICAL CONCERNS: The symptoms of acute and chronic hepatitis
include fever, malaise, nausea, and pain, any or all of which could be
distracting in an aviation mission.
Acute Hepatitis A or E: Personnel will be grounded until the liver enzymes
have returned to normal, but then may be returned to full flying duty
without further action.
Treatment with alpha interferon and or lamividine has been shown to moderate
signs of chronic HBV infection and eliminates HBeAg in one third of patients,
with eventual clearance of HBsAg in some of the responders.
For those patients whose hepatitis is a result of infection with hepatitis-B
virus as an adult, 10% progress to chronic disease; cases arising in childhood
progress to chronicity more frequently.
hepatitis
http://www.professionalnurse.com/download/hepatitis.pdf OSHA requires that all health care workers at risk of acquiring
Hepatitis B have the opportunity to receive the Hepatitis B vaccination
by their employer.
Further, I understand that I will be provided appropriate training at
my assigned workplace and will adhere to the procedures of the facilities
to which I am assigned by PNS staffing.
I have been given the opportunity to be vaccinated with hepatitis B vaccine,
at no charge to me, while on active assignment with PNS Staffing.
If in the future I continue to have occupational exposure to blood or
other infectious materials and I want to be vaccinated with the Hepatitis
B vaccine I can receive the vaccination series at no charge to myself,
while on assignment with PNS Staffing.
hepb00
http://www.lapublichealth.org/acd/reports/annual/cd00/hepb00.pdf Hepatitis B is a vaccine-preventable disease transmitted through
parenteral or mucous membrane exposure to the blood and other body fluids
of individuals infected with the hepatitis B virus (HBV), a DNA-virus
of the Hepadnaviridae family.
Death from cirrhosis or liver cancer is estimated to occur in 15-25% of
those with chronic infection.
Multiple ual partners remained the most frequently identified risk
factor.
Since 1999, there was an increase in cases among younger adults aged 15-34
years (Figure 42).
The majority of these reports do not provide a definitive diagnosis or
enough information to designate a case as acute or chronic.
Hep C2002
$FILE/Hep C2002.pdf HCV is spread by coming into contact with the blood of a person
who is infected with the virus.
Although HCV is not commonly spread during , being HIV positive may
make the ual transmission of HCV easier.
In a process that takes many years, HCV infection slowly spreads throughout
the liver and perhaps into other parts of the body, though only the liver
appears to show any damage.
Sulkowski MS, Moore RD, Mehta SH, et al. Hepatitis C and progression of
HIV disease.
Information accessed through or published or provided by CATIE, however,
is not to be considered medical advice.
Instr Hepatitis B 99
http://www.esr.cri.nz/features/surveillance/Case
Report Form Instructions/Instr Hepatitis B 99.pdf Indicate whether the case is hepatitis B, C or NOS (Not Otherwise
Specified).
Use NOS for cases of hepatitis D or E or if the type of hepatitis has
not been determined.
If not known or unavailable then tick the "Unknown" box.
Indicate the status of laboratory confirmation for the disease specified.
Specify any other risk factors under surveillance for the disease if they
were present.
If the case has been immunised record the details of each dose they received.
Clinical description An illness with variable symptoms including fever,
malaise and anorexia with jaundice and/or elevated serum aminotransferase
levels.
